19 research outputs found
Synthetic Nanoparticles for Vaccines and Immunotherapy
The immune system plays a critical role in our health. No other component of human physiology plays a decisive role in as diverse an array of maladies, from deadly diseases with which we are all familiar to equally terrible esoteric conditions: HIV, malaria, pneumococcal and influenza infections; cancer; atherosclerosis; autoimmune diseases such
as lupus, diabetes, and multiple sclerosis. The importance of understanding the function of the immune system and learning how to modulate immunity to protect against or treat disease thus cannot be overstated. Fortunately, we are entering an exciting era where the
science of immunology is defining pathways for the rational manipulation of the immune system at the cellular and molecular level, and this understanding is leading to dramatic advances in the clinic that are transforming the future of medicine.1,2 These initial advances are being made primarily through biologic drugsâ recombinant proteins (especially antibodies) or patient-derived cell therapiesâ but exciting data from preclinical studies suggest that a marriage of approaches based in biotechnology with the materials science and chemistry of nanomaterials, especially nanoparticles, could enable more effective and safer immune engineering strategies. This review will examine these nanoparticle-based strategies to immune modulation in detail, and discuss the promise and outstanding challenges facing the field of immune engineering from a chemical biology/materials engineering perspectiveNational Institutes of Health (U.S.) (Grants AI111860, CA174795, CA172164, AI091693, and AI095109)United States. Department of Defense (W911NF-13-D-0001 and Awards W911NF-07-D-0004
Boosting teenagers with acellular pertussis vaccines containing recombinant or chemically inactivated pertussis toxin: A randomized clinical trial
Background
Protection induced by acellular pertussis (aP) vaccines is partial and short-lived, especially in teenagers, calling for novel immunization strategies.
Methods
We conducted an investigator-driven proof-of-concept randomized controlled trial in aP-primed adolescents in Geneva to assess the immunogenicity and reactogenicity of a novel recombinant aP (r-aP) vaccine including recombinant pertussis toxin (PT) and filamentous hemagglutinin (FHA) coadministered with tetanus-diphtheria toxoids (Td), compared to a licensed tetanus-diphtheria-aP vaccine containing chemically detoxified PT (cd/Tdap). The primary immunological endpoints were day 28/365 geometric mean concentrations (GMCs) of total and neutralizing anti-PT antibodies. Memory B cells were assessed.
Results
Sixty-two aP-primed adolescents were randomized and vaccinated with r-aP + Td or cd/Tdap. Reactogenicity, adverse events, and baseline GMCs were similar between the groups. Day 28 PT-neutralizing GMCs were low after cd/Tdap (73.91 [95% confidence interval {CI}, 49.88â109.52] IU/mL) and approximately 2-fold higher after r-aP + Td (127.68 [95% CI, 96.73â168.53] IU/mL; P = .0162). Anti-PT GMCs were also low after cd/Tdap (52.43 [95% CI, 36.41â75.50] IU/mL) and 2-fold higher after r-aP + Td (113.74 [95% CI, 88.31â146.50] IU/mL; P = .0006). Day 28 anti-FHA GMCs were similar in both groups. Day 365 anti-PT (but not PT-neutralizing) GMCs remained higher in r-aP + Td vaccinees. PT-specific memory B cells increased significantly after r-aP + Td but not cd/Tdap boosting.
Conclusions
Boosting aP-primed adolescents with r-aP induced higher anti-PT and PT-neutralizing responses than cd/Tdap and increased PT-specific memory B cells. Despite this superior immunogenicity, r-aP may have to be given repeatedly, earlier, and/or with novel adjuvants to exert an optimal influence in aP-primed subjects.
Clinical Trials Registration
NCT02946190.</p
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.
Protection induced by acellular vaccines can be short, requiring novel immunization strategies. Objectives of this study were to evaluate safety and capacity of a recombinant pertussis toxin (PTgen) -coated ViaskinÂź epicutaneous patch to recall memory responses in healthy adults. This double-blind, placebo-controlled randomized trial (Phase I) assessed the safety and immunogenicity of PTgen administered on days 0 and 14 to healthy adults using ViaskinÂź patches applied directly or after epidermal laser-based skin preparation. Patch administration was followed by BoostrixÂźdTpa on day 42. Antibodies were assessed at days 0, 14, 28, 42 and 70. Among 102 volunteers enrolled, 80 received Viaskin-PT (Viaskin-PT 25 ÎŒg (n = 25), Viaskin-PT 50 ÎŒg (n = 25), laser + Viaskin-PT 25 ÎŒg (n = 5), laser + Viaskin-PT 50 ÎŒg (n = 25)), Viaskin-placebo (n = 10) or laser + Viaskin-placebo (n = 2). Incidence of adverse events was similar across groups (any local event: 21/25 (84.0%), 24/25 (96.0%), 4/5 (80.0%), 24/25 (96.0%), 8/10 (80.0%), 10/12 (83.0%), respectively). Direct application induced no detectable response. On day 42, PT-IgG geometric mean concentrations were significantly higher following laser + Viaskin-PT 25 ÎŒg and 50 ÎŒg (139.87 (95% CI 87.30-224.10) and 121.76 (95% CI 95.04-156.00), respectively), than laser + Viaskin-placebo (59.49, 95% CI 39.37-89.90). Seroresponse rates were higher following laser + Viaskin-PT 25 ÎŒg (4/5 (80.0%), 95% CI 28.4-99.5) and 50 ÎŒg (22/25 (88.0%), 95% CI 68.8-97.5) than laser + Viaskin-placebo (0/12 (0.0%), 95% CI 0.0-26.5). Viaskin-PT applied after laser-based epidermal skin preparation showed encouraging safety and immunogenicity results: anti-PT booster responses were not inferior to those elicited by BoostrixÂźdTpa. This study is registered at ClinicalTrials.gov (NCT03035370) and was funded by DBV Technologies
Macrophage-Specific Targeting of Isoniazid Through Mannosylated Gelatin Microspheres
Active targeting of drug molecules can be achieved by effective attachment of suitable ligands to the surface of carriers. The present work was attempted to prepare mannosylated gelatin microspheres (m-GMs) so as to achieve targeted delivery of isoniazid (INH) to alveolar macrophages (AMs) and maintain its therapeutic concentration for prolonged period of time. Microspheres were prepared by emulsification solvent extraction method and evaluated for physicochemical characteristics, drug release, ex vivo drug uptake by AMs and pharmacokinetic characteristics. Fourier transform infrared spectroscopy and nuclear magnetic resonance spectral analysis confirmed that mannosylation took place through Schiff base formation between aldehyde and amino groups of mannose and gelatin, respectively. Prepared microspheres offered suitable physicochemical characteristics for their delivery to AMs. Their average size was about 4Â ÎŒm and drug entrapment efficiency of 56% was achieved with them. Ex vivo uptake results indicated that in comparison to plain microspheres, m-GMs were selectively uptaken and were found to be associated with phago-lysosomal vesicles of AMs. Pharmacokinetic studies showed the formulation could maintain the therapeutic concentration of INH for prolonged period of time even with a reduced clinical dose. m-GMs were found to be stable in broncheo-alveolar lavage fluid. The study concluded that ligand decorated carriers could be a potential strategy to improve the therapeutic properties of INH
Development and Characterization of Biocompatible Mannose Functionalized Mesospheres: an Effective Chemotherapeutic Approach for Lung Cancer Targeting
Comparative pharmacokinetics of PAMAM-OH dendrimers and HPMA copolymers in ovarian tumor-bearing mice
Tuftsin-Modified Alginate Nanoparticles as a Noncondensing Macrophage-Targeted DNA Delivery System
Mannose-Functionalized âPathogen-likeâ Polyanhydride Nanoparticles Target C-Type Lectin Receptors on Dendritic Cells
Targeting pathogen recognition receptors ondendritic cells (DCs) offers the advantage of triggering specificsignaling pathways to induce a tailored and robust immuneresponse. In this work, we describe a novel approach to targetedantigen delivery by decorating the surface of polyanhydridenanoparticles with specific carbohydrates to provide âpathogenlikeâproperties that ensure nanoparticles engage C-type lectinreceptors on DCs. The surface of polyanhydride nanoparticleswas functionalized by covalent linkage of dimannose and lactoseresidues using an amine carboxylic acid coupling reaction.Coculture of functionalized nanoparticles with bone marrow derivedDCs significantly increased cell surface expression ofMHC II, the T cell costimulatory molecules CD86 and CD40,the C-type lectin receptor CIRE and the mannose receptorCD206 over the nonfunctionalized nanoparticles. Both nonfunctionalizedand functionalized nanoparticles were efficientlyinternalized by DCs, indicating that internalization of functionalizednanoparticles was necessary but not sufficient to activateDCs. Blocking the mannose and CIRE receptors prior to theaddition of functionalized nanoparticles to the culture inhibited the increased surface expression of MHC II, CD40 and CD86.Together, these data indicate that engagement of CIRE and the mannose receptor is a key mechanism by which functionalizednanoparticles activate DCs. These studies provide valuable insights into the rational design of targeted nanovaccine platforms toinduce robust immune responses and improve vaccine efficacy